Context: Follow-up after adrenalectomy for pheochromocytoma is recommended because of a recurrence risk. During follow-up, plasma and/or urinary metanephrine (MN) and normetanephrine (NMN) are interpreted using reference ranges obtained in healthy subjects.
INTRODUCTION
Pheochromocytomas are rare catecholamine-producing tumors, derived from adrenal chromaffin tissue1. Pheochromocytomas occur sporadically or as part of several hereditary tumor syndromes, such as multiple endocrine neoplasia (MEN) type 2, von Hippel-Lindau syndrome, neurofibromatosis type 1 and in the context of succinate dehydrogenase (SDH) mutations2. In pheochromocytoma patients, the demonstration of excessive production of catecholamines and their 3-O-methylated metabolites, metanephrine (MN) and normetanephrine (NMN), constitutes the cornerstone of biochemical diagnosis3-5. In healthy individuals, the adrenal medulla together with the sympathetic nervous system represent the main sources of catecholamine production and metabolism6 (Figure 1 is cortisol-dependent, the adrenal medulla is main source of MN measured in urine and/or plasma6, 9. Resection of a pheochromocytoma through adrenalectomy is indicated to prevent potentially fatal complications due to catecholamine excess10,11. Postoperatively, periodic measurement of plasma and/or urinary MN and NMN is performed in order to monitor for recurrent disease.
Follow-up is recommended 2 to 3 months postoperatively, annually during the first 5 years, and once every 2 years thereafter12. During long-term follow-up, 6-16% of tumors recur within 10 years postoperatively, but tumor recurrences have been described even after 15 years13-15. Follow-up is especially important for patients with hereditary tumor syndromes, as these individuals have an increased risk for developing a pheochromocytoma in the contralateral adrenal gland13,14.
In routine clinical practice, the concentrations of urinary and/or plasma MN and NMN found in patients after adrenalectomy are interpreted by using reference intervals established in healthy subjects. However, unilateral or bilateral adrenalectomy is expected to be followed by a decrease of epinephrine and, consequently, lower plasma and urinary MN concentrations. Use of incorrect reference intervals may interfere with early detection of tumor recurrence, e.g. when the associated rise in MN concentration occurs within the reference range applicable to healthy individuals with normally functioning adrenal glands. Currently, there is no detailed information on the influence of adrenalectomy on epinephrine and norepinephrine concentrations.
Therefore, the aim of this cohort study was to compare the urinary and plasma MN and NMN concentrations in patients who underwent unilateral or bilateral adrenalectomy for a pheochromocytoma with those determined in a healthy reference population.
MATERIALS AND METHODS

Study population
We retrospectively studied patients above 20 years of age at the time of diagnosis who had undergone either bilateral or unilateral adrenalectomy for pheochromocytoma at the University Medical Center of Groningen between January 1980 and August 2011. This period was chosen because assays of fractionated total metanephrines in urine with gas chromatography-mass spectrometry and plasma fractionated free metanephrines with liquid chromatography tandem mass spectrometry (LC-MS/MS) have been available at our institution since 1979 and 2005, respectively. The diagnosis of a pheochromocytoma was histologically confirmed in all patients.
Postoperative concentrations of metanephrines had to be available for at least one follow-up visit after adrenalectomy. Exclusion criteria were a recurrent tumor within five years of surgery, a partial (i.e. cortical-sparing) adrenalectomy and incomplete resection of the tumor. Patients who presented with a concurrent extra-adrenal paraganglioma were also excluded. Preferably, tumor recurrence had to be confirmed by histology. In cases lacking this information, a diagnosis of tumor recurrence was based on the combined results of anatomical and functional imaging.
The initial clinical diagnosis of a pheochromocytoma was based on elevated urinary and/ or plasma MN and NMN concentrations and localization of the tumor with anatomical imaging of both adrenal glands (computed tomography (CT)/ magnetic resonance imaging (MRI)) as well as whole body functional imaging with ¹²³I-metaiodobenzylguanidine (MIBG) scintigraphy or 18 F-dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) (available at our institution since 2003). Long-term follow-up was performed by measurement of urinary and/or plasma metanephrines. Anatomical and/or functional imaging was repeated in patients with persistently elevated metanephrines, in order to localize recurrent disease. In accordance with international guidelines, patients below 50 years of age were tested for germline mutations16-19. In patients above 50 years of age, the family history was checked to evaluate the risk for hereditary syndromes. 
Analytical Methods
Isotope-dilution mass spectrometry-based measurements of urinary and/or plasma metanephrines were used. Urinary deconjugated metanephrine concentrations were determined by isotopediluting gas chromatography-mass spectrometry, as described by Muskiet et al. 23, 24 . Urinary deconjugated metanephrine concentrations were normalized to the urinary excretion of creatinine, measured using a picric acid-based method (before 2005) or an enzymatic method (Roche Diagnostics, Almere, the Netherlands) (after 2005), and expressed in units of µmol/mol creatinine.
The intra-assay variation coefficient was 1.7-4.2% and the inter-assay variation coefficient was 3.3-15.4%. Reference intervals for urinary metanephrines were as follows: MN 33-99 µmol/mol creatinine, NMN 64-260 µmol/mol creatinine.
Plasma free metanephrine assays were performed with a HPLC tandem mass spectrometric technique (LC-MS/MS) with automated solid phase extraction sample preparation, as described by de Jong et al. 22 . Established reference intervals for plasma free metanephrines were: MN 0.07-0.33 nmol/L, NMN 0.23-1.07 nmol/L. The intra-assay and inter-assay variation coefficients were 2.5-4.8% and 3.4-5.6% for the free plasma MN measurement, and 5.1-6.2% and 4.2-7.1% for the free plasma NMN measurements.
Statistics
Data are presented as mean (+ standard deviation (SD)) or as median [interquartile ranges (IQR)] where appropriate. Differences between urinary metanephrines in healthy subjects and patients after unilateral or bilateral adrenalectomy were evaluated using the Mann-Whitney U test with 
RESULTS
Patient characteristics
Between January 1980 and August 2011, 108 pheochromocytoma patients underwent a unilateral or bilateral adrenalectomy at our institution. Of these, 14 patients (13.0%) were excluded. Reasons for exclusion were missing laboratory data (n=4), subtotal adrenalectomy (n=1) and recurrent disease (n=9) within five years after adrenalectomy. Preoperatively, all patients were treated with adrenergic receptor antagonists to prevent potentially fatal complications of surgery. At 3 to 6 months after adrenalectomy, 24 patients (25.5%) used anti-hypertensive medication, of whom 13 used beta-adrenergic receptor antagonists (13.8%). 
Postoperative deconjugated urinary and plasma free MN concentrations
In patients who underwent a unilateral adrenalectomy, the median urinary and plasma MN concentration were significantly lower 3 to 6 months after unilateral adrenalectomy compared with the reference population (both P<.05), as shown in (Figure 3 ). The plasma MN concentration was available for only 2 patients, and was 0.01 and 0.03 nmol/L, at 3 to 6 months, -respectively; therefore, no statistical comparison was made ( Table 2 ). The urinary MN concentration of 17 patients with MEN type 2A 3 to 6 months after bilateral adrenalectomy was 4 (1-11.8) µmol/ mol creatinine, which was lower compared to the reference population (P<.05).
Postoperative deconjugated urinary and plasma free NMN concentrations
Median urinary and plasma NMN concentrations in patients after unilateral adrenalectomy were higher compared with the reference population 3 to 6 months after unilateral adrenalectomy (both P<.05) ( In patients who underwent a bilateral adrenalectomy, the median urinary NMN concentration significantly increased compared to the reference population (P<.05). Three patients (16.7%) had a urinary NMN concentration above the URL 3 to 6 months after bilateral adrenalectomy with concentrations ranging from 382 to 430 µmol/mol creatinine. There were no changes during the 5 years of follow-up in the urinary NMN after bilateral adrenalectomy (averaged correlation coefficient: -0.00; P=.972) (Figure 3 ). The plasma NMN concentration was 0.52 and 0.67 nmol/L 3 to 6 months after bilateral adrenalectomy in the 2 patients in whom this was available. The urinary NMN concentration of 17 patients with MEN type 2A 3 to 6 months after bilateral adrenalectomy was higher compared to the reference population, 177 (102-232) µmol/mol creatinine (P=.09).
In 17 patients (18.1%) an increased urinary and/or plasma NMN concentration was found during one or more follow-up moments in the 5-year follow-up period. In seven out of these 17 patients, additional imaging with CT (n= 2), MRI (n=2), ¹²³I -MIBG (n=5), 18 F-DOPA PET (n=2), 111 In-Octreoscan (n=1) or a clonidine suppression test (n=1) was performed with no evidence of recurrent disease.
In all these 17 patients the NMN concentration normalized during follow-up without intervention. 
DISCUSSION
In the present study, we found that MN concentrations in both plasma and urine after unilateral and bilateral adrenalectomy were persistently lower compared with the values obtained in a reference population consisting of healthy subjects. As expected, this difference was most profound in patients after bilateral adrenalectomy. In contrast, we found that NMN concentrations in both plasma and urine in patients after adrenalectomy were higher than in healthy subjects.
Two previous studies have described the catecholamine and metanephrine concentration after had Cushing's syndrome, and one patient had a pheochromocytoma. In concordance with our study, they found that the plasma epinephrine concentration was below the limit of detection, and plasma concentrations of free and conjugated MN were decreased compared with healthy control subjects. Plasma NMN concentrations, however, were unaffected in that study26. It should be noted that the present study is considerably larger, includes patients after unilateral adrenalectomy and contains long-term follow-up data. Furthermore, the liquid chromatography with electrochemical detection used in the latter study is more susceptible to interference and has a higher detection limit and is therefore not as accurate as the LC-MS/MS technique we applied27.
Although we observed a small statistically significant increase of 4 μmol/mol creatinine in the urinary MN concentration during the five-year follow-up, the urinary MN concentration in persistently lower after unilateral adrenalectomy. This implies that the contralateral adrenal gland cannot fully compensate for the loss of production and secretion of epinephrine. The detection of MN in patients after bilateral adrenalectomy, suggests that epinephrine production might take place outside the adrenal gland. This is supported by the demonstration of positive immunohistochemical staining for PNMT in adrenergic cells present in fetal rat hearts and in rat adipocytes28-30.
There might be several explanations for the observed increase in postsurgical NMN concentrations.
Most likely, this increase is explained by an augmented production of norepinephrine in sympathetic nerves, thereby compensating for the loss of epinephrine activity in maintaining vascular tone.
Alternatively, this phenomenon could also result from desensitization of α-and β-receptors due to the high amount of circulating catecholamines before adrenalectomy, but this phenomenon is temporary and therefore expected to resolve after adrenalectomy31. Because patients with tumor recurrence within five years after surgery were excluded, the increase can not be attributed to a recurrent pheochromocytoma. This is additionally supported by the observation that the increase in NMN concentrations had already occurred 3 to 6 months postoperatively and the increase thereafter was only marginal. False-positive results caused by analytical interference are not likely because we used mass spectrometric detection, which is known for its very high analytical specificity22. It could be argued that our results might be confounded by preanalytical factors such as pharmacological interference by antihypertensive drugs, the lack of dietary restrictions, or patient positioning during blood sampling. However, analyzing patients without antihypertensive medication did not change the results (data not shown). In the present study, blood was collected while healthy subjects and patients were seated. It has been demonstrated that plasma metanephrines are moderately elevated in the seated compared to the supine position32. Our conclusions, however, will not be affected by the position during sampling, because the postoperative concentrations of plasma were compared with the reference population in whom blood sampling had also been performed in the seated position. In addition, the concomitant increase in 24-hour urinary NMN concentrations argues against a possible influence of body position during blood collection. Dietary restrictions of catecholamine-rich food supplies are considered to minimize the possibility of false-positive results for urinary deconjugated NMN concentrations. We found decreased concentrations of both urinary deconjugated and plasma free NMN concentrations. Therefore, it seems unlikely that diet is a confounding factor21.
Our results strongly suggest that the diagnostic yield of the measurement of metanephrines in plasma or urine is negatively affected by adrenalectomy. The decrease in MN levels is expected to reduce the sensitivity, whereas the increase in NMN levels after adrenalectomy is likely to lower the specificity of this assay. Consequently, adjusted reference intervals are needed for patients with pheochromocytoma after unilateral or bilateral adrenalectomy. Downward adjustment of the MN reference ranges in these patients could thus contribute to an earlier detection of tumor recurrence, whereas upward adjustment of the NMN reference ranges could prevent unnecessary diagnostic tests. The latter might be particular relevant for patients with von Hippel-Lindau syndrome, which is accompanied by an increased secretion of NMN33. According to current knowledge, additional imaging could have been prevented during follow-up in 7 out of 94 patients (7.5%) seen in our hospital after adrenalectomy because of a pheochromocytoma. Because imaging was not performed in patients with MN concentrations within the reference intervals, we cannot give an indication about how much sooner tumor recurrence would have been detected with adjusted reference intervals for MN. Specific reference intervals for urine and/or plasma MN and NMN need to be established in patients after adrenalectomy in order to improve both sensitivity and specificity for this patient group. Partial adrenalectomy is an emerging alternative procedure reducing the risk of adrenal insufficiency when performed by an experienced surgeon. Because the adrenal medulla is complete resected in partial adrenalectomy, the effects on the catecholamine secretion after successful resection of the pheochromocytoma are comparable with patients after complete adrenalectomy34,35. We, therefore, believe that our results are also applicable in patients after partial adrenalectomy.
Our study has some limitations. Because of the retrospective nature of this study, not all data are complete. Plasma metanephrine concentrations after bilateral adrenalectomy were available in only a few patients, as this particular assay was only introduced in our laboratory after 2005. Patients with tumor recurrence after adrenalectomy within the observation period were excluded, but followup was shorter than five years in a minority of patients. In particular, in patients with hereditary tumor syndromes, tumor recurrence could not always be completely excluded even in the absence of detectable tumor on imaging. Furthermore, the number of patients was too small to perform statistical tests on the different hereditary groups. However, analyzing patients with MEN type 2a after bilateral adrenalectomy gave comparable with the results.
From these data, it can be concluded that adrenalectomy in pheochromocytoma patients results in a new set point in catecholamine production, with lower epinephrine and higher norepinephrine secretion. We therefore recommend the use of adapted reference intervals in the follow-up of pheochromocytoma patients after adrenalectomy. These reference intervals need to be established prospectively in a large population of patients who have underwent surgery for a sporadic or hereditary pheochromocytoma. These adapted reference intervals for metanephrines would be expected to enable both earlier detection of recurrent disease and prevent unnecessary diagnostic testing.
